StockData
CATXNYSEPharmaceutical PreparationsFiscal year ends December 31

Perspective Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.19+0.02 (+0.92%)

Close on Oct 19, 2026

Market cap
$264.23M
P/E (TTM)
–
Dividend yield
–

Perspective Therapeutics, Inc. revenue by segment

No segment breakdown reported

Perspective Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.